BOSTON--(BUSINESS WIRE)--Expansion Therapeutics, Inc., a biotechnology company advancing transformative medicines to patients with RNA-mediated diseases, today announced the appointment of Mark Ledeboer, Ph.D. to Senior Vice President of Drug Discovery.
“Mark is a proven leader and drug hunter with more than 20 years of experience in the biotech industry and broad drug discovery expertise across a range of therapeutic areas, including central nervous system, oncology, inflammation and immunology,” said Renato Skerlj, Ph.D., Chief Executive Officer and President of Expansion Therapeutics. “His impressive background, coupled with his track record of success heading fully integrated drug discovery programs, will be extremely valuable to Expansion as we advance our pipeline into the clinic.”
In his role at Expansion, Dr. Ledeboer will lead the discovery efforts from early stage to development candidate to first-in-human studies and direct all internal and external discovery activities. He will be responsible for all aspects of the discovery process required to identify a development candidate as well late-stage activities to support clinical development. “I am excited to join Expansion and look forward to working with an esteemed group of colleagues to build a successful research organization and deliver drugs to help patients with high unmet medical needs,” said Dr. Ledeboer.
Over the course of his career in medicinal chemistry and drug discovery, Dr. Ledeboer has contributed to the discovery and development of multiple drug candidates and is listed as a co-inventor on more than 20 patents. He formerly served as Vice President, Head of Drug Discovery and Head of Chemistry at Goldfinch Bio where he successfully led a multifunctional discovery project team that delivered and advanced the company’s lead asset, GFB-887, which is currently in Phase 2 development for focal segmental glomerulosclerosis.
Prior to his position with Goldfinch Bio, Dr. Ledeboer held various roles of increasing responsibility in drug discovery at Vertex Pharmaceuticals where he was a research fellow in Medicinal Chemistry. Dr. Ledeboer holds a Ph.D. and M.A. in Organic Chemistry from Brown University and completed his postdoctoral fellowship at The Scripps Research Institute based in La Jolla, California. He received his Bachelor of Science degree in Chemistry from Lafayette College.
About Expansion Therapeutics
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Based on exclusive worldwide rights to groundbreaking research from the laboratory of Matthew D. Disney, Ph.D., at Scripps Research, Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule binders of RNA. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of disease indications. Headquartered in Boston, Massachusetts, Expansion’s research facility is located in Jupiter, Florida. For more information, visit www.expansionrx.com.